Local and systemic cytokine profiles in nonsevere and severe community-acquired pneumonia

Local inflammatory responses in community-acquired pneumonia (CAP) remain insufficiently elucidated, especially in patients with nonsevere CAP. In this study we determined local and systemic cytokine responses in CAP patients and correlated these with disease severity and other clinical parameters. Levels of interleukin (IL)-6, IL-8, IL-10, IL-1&bgr;, tumour necrosis factor-&agr;, interferon (IFN)-&ggr;, IL-22, IL-17A and IL-4 were determined in bronchoalveolar lavage fluid and serum of 20 CAP patients upon admission and 10 healthy individuals. Systemic cytokine levels were also measured on days 7 and 30. In bronchoalveolar lavage fluid of CAP patients, levels of IL-6, IL-8 and IFN-&ggr; were significantly increased compared with healthy individuals, but no correlations with disease severity were found. Systemic levels of IL-6, IL-10 and IFN-&ggr; were significantly higher in severe CAP patients than in nonsevere CAP patients and healthy individuals. Moreover, these cytokines showed a significant correlation with the pneumonia severity index. In the total group of CAP patients, systemic IL-8 and IL-22 levels were also increased compared with healthy individuals. We therefore conclude that IL-6, IL-10 and IFN-&ggr; are important cytokines in CAP, although differences in disease severity upon admission are only reflected by systemic levels of these cytokines.

[1]  A. Torres,et al.  Cytokine Activation Patterns and Biomarkers Are Influenced by Microorganisms in Community-Acquired Pneumonia , 2012, Chest.

[2]  I. Moret,et al.  Increased lung neutrophil apoptosis and inflammation resolution in nonresponding pneumonia , 2011, European Respiratory Journal.

[3]  H. Endeman,et al.  Systemic cytokine response in patients with community-acquired pneumonia , 2010, European Respiratory Journal.

[4]  C. Esquinas,et al.  Factors associated with inflammatory cytokine patterns in community-acquired pneumonia , 2010, European Respiratory Journal.

[5]  T. Standiford,et al.  Cooperative Interactions between TLR4 and TLR9 Regulate Interleukin 23 and 17 Production in a Murine Model of Gram Negative Bacterial Pneumonia , 2010, PloS one.

[6]  Chia-Hung Chen,et al.  Systemic and bronchoalveolar cytokines as predictors of in-hospital mortality in severe community-acquired pneumonia. , 2010, Journal of critical care.

[7]  S. Opal,et al.  Clinical review: The role of biomarkers in the diagnosis and management of community-acquired pneumonia , 2010, Critical Care.

[8]  C. Esquinas,et al.  Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia , 2009, Thorax.

[9]  M. Fei,et al.  IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia , 2008, Nature Medicine.

[10]  John A Kellum,et al.  Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. , 2007, Archives of internal medicine.

[11]  P. Ridker,et al.  Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms , 2005, Nature Reviews Drug Discovery.

[12]  M. Cazzola,et al.  Inflammation – A New Therapeutic Target in Pneumonia , 2005, Respiration.

[13]  V. Armstrong,et al.  Circulating cytokines as markers of systemic inflammatory response in severe community-acquired pneumonia. , 2004, Clinical biochemistry.

[14]  M. Belvisi.  Regulation of inflammatory cell function by corticosteroids. , 2004, Proceedings of the American Thoracic Society.

[15]  I. Uçgun,et al.  Acute Phase Reactants and Cytokine Levels in Unilateral Community-Acquired Pneumonia , 2003, Respiration.

[16]  C. Hack,et al.  Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection. , 2002, Clinical immunology.

[17]  A. Frew,et al.  Systemic cytokine levels in community-acquired pneumonia and their association with disease severity , 2002, European Respiratory Journal.

[18]  Y. Koh,et al.  Levels of interleukin-2, interferon-gamma, and interleukin-4 in bronchoalveolar lavage fluid from patients with Mycoplasma pneumonia: implication of tendency toward increased immunoglobulin E production. , 2001, Pediatrics.

[19]  A. Fraise,et al.  British Thoracic Society guidelines on diagnostic flexible bronchoscopy. , 2001, Thorax.

[20]  A. Torres,et al.  Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. , 1999, Critical care medicine.

[21]  S. O’Neill,et al.  Circulating interleukin 6 and interleukin 10 in community acquired pneumonia. , 1999, Thorax.

[22]  Sheldon P Stone,et al.  Community-acquired pneumonia , 1998, The Lancet.

[23]  J. Rubins,et al.  Role of gamma interferon in the pathogenesis of bacteremic pneumococcal pneumonia , 1997, Infection and immunity.

[24]  M. Fine,et al.  A prediction rule to identify low-risk patients with community-acquired pneumonia. , 1997, The New England journal of medicine.

[25]  W. Seeger,et al.  Bronchoalveolar and systemic cytokine profiles in patients with ARDS, severe pneumonia and cardiogenic pulmonary oedema. , 1996, The European respiratory journal.

[26]  B. Crestani,et al.  Compartmentalized IL-8 and elastase release within the human lung in unilateral pneumonia. , 1996, American journal of respiratory and critical care medicine.

[27]  A. Puren,et al.  Patterns of cytokine expression in community-acquired pneumonia. , 1995, Chest.

[28]  B. Crestani,et al.  Compartmentalized cytokine production within the human lung in unilateral pneumonia. , 1994, American journal of respiratory and critical care medicine.

[29]  J. Cavaillon,et al.  Characterization of the Induction of Human Interleukin 1 by Endotoxins , 1987 .